Nine new vanadium complexes, with tridentate Schiff base ligand based on 3,5-di-tertbutyl-2-hydroxybenzaldehyde and different hydrazides, are described and characterized. The X-ray crystal structure of complex 8 shows distorted octahedral geometry of vanadium, with ONO ligand in equatorial position. The tridentate Schiff base ligand forms six membered and five-membered chelate rings at the V(V) acceptor center, with the corresponding bite angles being 82.97(9)˚ and 74.48(9)˚. The molecules are gathered by means of intermolecular OH...N hydrogen bond and layered by π...π interactions involving the pyridine and phenolate rings. Such interactions expand the structure along the crystallographic a axis. The complexes were characterized by the elemental analyses, IR, UV-Vis, EPR spectroscopy, cyclic voltammetry, thermogravimetry and magnetic susceptibility measurements. The stabilization role of co-ligands is discussed. The cytotoxicity versus HepG2 hepatocytes and inhibition of human recombinant PTP1B was studied.
The synthesis and physicochemical properties of three new complexes of vanadium at +5, +4 and +3 oxidation state are described and discussed. The octahedral surrounding of vanadium for V(III) complexes of [V(L1)(HL1)] general formula is filled with two ONO tridentate ligand L, for V(IV) one ONO ligand L, oxido ligand and 1,10-phenanthroline (phen) as a co-ligand are presented in complexes of [VO(L2)(phen)]. For V(V) the complexes of [VO2(L1)(solv)] type were formed. As ligands, the H2L Schiff bases were formed in reaction between 5-hydroxysalcylaldehyde and phenylacetic hydrazide (H2L1) and 3,5- dichlorosalicyaldehyde and 4-hydroxybenzhydrazide (L2). The magnetic moment measurements, in 8 year period, show, that V(III) complexes slowly oxidise to V(IV) with preservation of the nonoxido character of the complexes, while V(IV) complexes were found to be stable. The TG and SDTA measurements indicate, that thermal stability depends mainly on the oxidation state of vanadium. The less thermally stable are the V(V) complexes, while V(IV) and V(III) are stable up to ca. 200oC. In solution, at pH 2 (similar to that in human digestion system), again the V(IV) are the most stable, only at pH 7.0 V(III) complexes had higher stability. The most stable, thus best for pharmaceutical use, are V(IV) complexes.
Vanadium is an element that has an effect on improving glucose levels in animals with diabetes. However, its operation is strongly dependent on the chemical structure of compounds of this element. The influence of newly synthesized vanadium compounds on biochemical processes is also unknown. The paper presents the influence of eight new vanadium compounds on organ weights of animals (mice NZO) in whom diabetes was induced by a high-fat diet during 8 weeks. Tested vanadium complexes were administered by 5 weeks. After this time organs were collected and weighed. Tested complexes had a remarkable different effect on organ weights, despite having similar composition ([VO(L)(phen)] and the same co-ligand (1,10-phenanthroline) . This indicate on separate metabolic pathways of these compounds in the body of tested animals and role of the tridentate L Schiff base ligands. The compounds C2, C3 and C5 shoved biggest influence on organs weight and these results suggest influence on the metabolic pathways and therefore are interesting for further investigations.
The oxidovanadium(V) Schiff base complex of formula [VO(L)(EtO)(EtOH)] (where H2L = Schiff base ligand derived from 5-methoxysalicylaldehyde and phenylacetic hydrazide) was synthesized and described. Complex crystalizes in triclinic P-1 space group. Octahedral geometry of the vanadium(V) centre is filed with oxido, ONO L2- ligand and two solvent molecules both in ethoxo and as neutral ethanol form. The complex is neutral, with 5- and 6-memebered ring formed by ONO ligand coordinated in octahedral plane with oxido and EtOH ligands in vertical positions. Two isomers are present in the unit cell, with different position of 5-membered ring versus vertical plane. The elemental analysis, magnetic susceptibility, thermogravimetry and spectroscopy (IR, UV-Vis) measurements were measured and are discussed. The cyclic voltammetry measurements show irreversible processes for vanadium(IV/V) redox system. Thermal stability both in a solid state (TG and SDTA measurements) as well as in solutions (at pH 7.0 and 2.0, studied by UV-Vis spectroscopy) is discussed.
The synthesis and physicochemical properties of new vanadium(IV) complex of formula [VO(L)(phen)] is described. The L denotes ONO tridentate Schiff base derived from 2,3-dihydroxybenzaldehyde and phenylacetic hydrazide, while phen = 1,10-phenanthroline used as a co-ligand to stabilize the V(IV) oxidation state. The single crystal X-Ray crystal structure indicates on octahedral geometry of vanadium centre, with 1,10-phenanthroline nitrogen trans to the V=O bond. The complex crystalizes in a monoclinic P21/c space group, very unusual is that only one isomer is present in the crystal structure. The structure is stabilized by very weak hydrogen bonds and H··π and π···π interactions. The phenyl ring of hydrazide is strongly curved from ONO ligand plane by 70.95˚. The spectroscopic characterization (IR, UV-Vis) as well as the cyclic voltammetry measurements are presented and discussed
The synthesis and physicochemical properties of vanadium(III,IV,V) complexes with Schiff base ligands based on 3,5-dibromo-4-methoxy-salicylaldehyde and phenylacetic hydrazide (H2L1), 5-chlorosalicylaldehyde and 4-hydroxybenzhydrazide (H2L2) and 5- chlorosalicylaldehyde and 2-hydroxybenzhydrazide (H2L3) were presented. The formulas of the complexes {[V(L1)(HL2)]·EtOH (1), [VO(L2)(phen)]·2H2O (2) and [VO(L3)(EtO)] (3)} were proposed based on the elemental analysis, IR and UV-Vis spectra. Additionally, the IR and UV-Vis spectra (in solvents as well as in a solid state) have been discussed from the vanadium oxidation state point of view. The single crystal structure of 3 shows triclinic, P-1 space group, structure is stabilized by hydrogen bonds and strong π-π stacking interactions. The oxidation state of the metal centre was also confirmed by the magnetic susceptibility measurements. The stability of the complexes was measured in pH = 7.00 and in pH = 2.00 which allows to evaluate the use of these compounds as insulin mimetic compounds.
Recent research on the action of vanadium compounds shows its important effect on adipogenesis processes and adipocyte function. On the basis of previous screening tests in cellular models, the novel vanadium complex (N′-[(E)-(5-bromo-2-oxophenyl)methylidene]4-methoxybenzohydrazide)oxido(1,10-phenanthroline)vanadium(IV) was selected for this study. This complex exhibits potent inhibition of tyrosine phosphatases, and differences in the degree of inhibition were observed particularly for phosphatases. A significant increase in intracellular lipid accumulation and proliferative effect on 3T3-L1 preadipocytes confirmed the ability of this complex to enhance adipogenesis. The insulinomimetic activity of the tested complex was also demonstrated in fully differentiated 3T3-L1 adipocytes, in which glucose utilization was potentiated. The obtained results support the hypothesis that vanadium complexes show promising possibilities for use as new therapeutic strategies for the treatment of type 2 diabetes.
In this study, 110 newly synthesized vanadium complexes from different structural groups were screened in three cell-based models representing the main target tissues for anti-diabetic drugs. In glucose utilization in C2C12 myocyte experiments, 93% of vanadium complexes were shown to have equal or greater activity than bis(maltolato)oxovanadium(IV) (BMOV), the methyl analog of bis(ethylmaltolato)oxovanadium(IV) (BEOV) which has been tested in clinical trials. Moreover, 49% and 50% of these complexes were shown to have equal or greater activity than BMOV in lipid accumulation in 3T3-L1 adipocytes and insulin secretion in RINm5F beta cell experiments, respectively. These results were the basis for the selection of compounds for the subsequent steps in the characterization of anti-diabetic properties. This study provides strong support for the application of screening cell-based assays with a phenotypic approach for the discovery of novel anti-diabetic drugs from the vanadium complex class. This is especially desirable due to the multiple and not fully defined mechanisms of action vanadium compounds.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.